Fair and Accurate Medicaid Pricing Act of 2019 or the Fair AMP Act
This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2019-06-11 | IntroReferral | Read twice and referred to the Committee on Finance. | Senate |
| 2019-06-11 | IntroReferral | Introduced in Senate | Library of Congress |